Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review, 14901 [2017-05733]
Download as PDF
<![CDATA[
Federal Register / Vol. 82, No. 55 / Thursday, March 23, 2017 / Notices
nomination period. Nominations
received after the closing date will be
marked as late and may be considered
only if time and resources permit.
significant current potential threat to
human health. The availability of the
revised list of the 275 SPL substances
was announced in April, 2015 on the
following Web site: https://
www.atsdr.cdc.gov/spl.
sradovich on DSK3GMQ082PROD with NOTICES
Substances To Be Evaluated for Set 31
Toxicological Profiles
Each year, ATSDR develops a list of
substances to be considered for
toxicological profile development. The
Set 31 nomination process includes
consideration of all substances on
ATSDR’s SPL, as well as other
substances nominated by the public.
The 275 substances on the SPL will be
considered for Set 31 Toxicological
Profile development. This list may be
found at the following Web site: https://
www.atsdr.cdc.gov/spl.
Submission of Nominations for the
Evaluation of Set 31 Proposed
Substances
ATSDR also will consider the
nomination of any substance that is not
on the SPL under the authority of the
Comprehensive, Environmental
Response, Compensation, and Liability
Act (CERCLA) to ‘‘. . . establish and
maintain an inventory of literature,
research, and studies on the health
effects of toxic substances’’ under
CERCLA Section 104(i)(1)(B), to respond
to requests for consultation under
section 104(i)(4), and to support the sitespecific response actions conducted by
ATSDR, as otherwise necessary.
Today’s document invites voluntary
public nominations for substances
included on the SPL and for substances
not listed on the SPL. All nominations
should include the full name of the
nominator, affiliation, and email
address. When nominating a non-SPL
substance, please include the rationale
for the nomination. Please note that
email addresses will not be posted in
the docket found at
www.regulations.gov.
ATSDR will evaluate all data and
information associated with nominated
substances and will determine the final
list of substances to be chosen for
toxicological profile development.
Substances will be chosen according to
ATSDR’s specific guidelines for
selection. These guidelines can be found
in the Selection Criteria announced in
the Federal Register on May 7, 1993 (58
FR 27286). A hard copy of the Selection
Criteria is available upon request or may
be accessed at: https://
www.atsdr.cdc.gov/toxprofiles/
guidance/criteria_for_selecting_tp_
support.pdf.
Please ensure that your comments are
submitted within the specified
VerDate Sep<11>2014
17:13 Mar 22, 2017
Jkt 241001
Pamela I. Protzel Berman,
Associate Director, Office of Policy, Planning
and Evaluation, National Center for
Environmental Health, Agency for Toxic
substances and Disease Registry.
[FR Doc. 2017–05736 Filed 3–22–17; 8:45 am]
BILLING CODE 4163–70–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Initial Review
The meeting announced below
concerns the Centers for Disease Control
and Prevention (CDC) initial review of
applications in response to Funding
Opportunity Announcement (FOA)
GH14–002, Addressing Emerging
Infectious Diseases in Bangladesh; and
FOA GH16–003, Conducting Public
Health Research in Thailand: Technical
collaboration with the Ministry of
Public Health in the Kingdom of
Thailand (MOPH).
SUMMARY: This publication corrects a
notice that was published in the Federal
Register on March 9, 2017 Volume 82,
Number 45, page 13119. The meeting
announcement and matters for
discussion should read as follows:
The meeting announced below
concerns the Centers for Disease Control
and Prevention (CDC) initial review of
applications in response to Funding
Opportunity Announcements (FOA)
GH13–001, Strengthening Disease
Prevention Research Capacity for Public
Health Action in Guatemala and the
Central American Region; FOA GH14–
002, Addressing Emerging Infectious
Diseases in Bangladesh; and FOA
GH16–003, Conducting Public Health
Research in Thailand: Technical
collaboration with the Ministry of
Public Health in the Kingdom of
Thailand (MOPH).
Matters for Discussion: The meeting
will include the initial review,
discussion, and evaluation of
applications received in response to
‘‘Strengthening Disease Prevention
Research Capacity for Public Health
Action in Guatemala and the Central
American Region’’, FOA GH13–001;
‘‘Addressing Emerging Infectious
Diseases in Bangladesh’’, FOA GH14–
002; and ‘‘Conducting Public Health
Research in Thailand: Technical
PO 00000
Frm 00037
Fmt 4703
Sfmt 9990
14901
collaboration with the Ministry of
Public Health in the Kingdom of
Thailand (MOPH)’’, FOA GH16–003.
FOR FURTHER INFORMATION CONTACT:
Hylan Shoob, Scientific Review Officer,
Center for Global Health (CGH) Science
Office, CGH, CDC, 1600 Clifton Road
NE., Mailstop D–69, Atlanta, Georgia
30033, Telephone: (404) 639–4796,
HMS4@CDC.GOV.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Claudette Grant,
Acting Director, Management Analysis and
Services Office, Centers for Disease Control
and Prevention.
[FR Doc. 2017–05733 Filed 3–22–17; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Clinical Laboratory Improvement
Advisory Committee (CLIAC)
Notice of Cancellation: This notice
was published in the Federal Register
on March 9, 2017, Volume 82, Number
45, page 13121. The meeting previously
scheduled to convene on April 12–13,
2017, has been canceled.
Contact Person for Additional
Information: Nancy Anderson, Chief,
Laboratory Practice Standards Branch,
Division of Laboratory Systems, Center
for Surveillance, Epidemiology and
Laboratory Services, Office of Public
Health Scientific Services, CDC, 1600
Clifton Road NE., Mailstop F–11,
Atlanta, Georgia 30329–4018; telephone
(404) 498–2741; or via email at
NAnderson@cdc.gov.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Claudette Grant,
Acting Director, Management Analysis and
Services Office, Centers for Disease Control
and Prevention.
[FR Doc. 2017–05731 Filed 3–22–17; 8:45 am]
BILLING CODE 4163–18–P
E:\FR\FM\23MRN1.SGM
23MRN1
]]>Agencies
[Federal Register Volume 82, Number 55 (Thursday, March 23, 2017)]
[Notices]
[Page 14901]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-05733]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Disease, Disability, and Injury Prevention and Control Special
Emphasis Panel (SEP): Initial Review
The meeting announced below concerns the Centers for Disease
Control and Prevention (CDC) initial review of applications in response
to Funding Opportunity Announcement (FOA) GH14-002, Addressing Emerging
Infectious Diseases in Bangladesh; and FOA GH16-003, Conducting Public
Health Research in Thailand: Technical collaboration with the Ministry
of Public Health in the Kingdom of Thailand (MOPH).
SUMMARY: This publication corrects a notice that was published in the
Federal Register on March 9, 2017 Volume 82, Number 45, page 13119. The
meeting announcement and matters for discussion should read as follows:
The meeting announced below concerns the Centers for Disease
Control and Prevention (CDC) initial review of applications in response
to Funding Opportunity Announcements (FOA) GH13-001, Strengthening
Disease Prevention Research Capacity for Public Health Action in
Guatemala and the Central American Region; FOA GH14-002, Addressing
Emerging Infectious Diseases in Bangladesh; and FOA GH16-003,
Conducting Public Health Research in Thailand: Technical collaboration
with the Ministry of Public Health in the Kingdom of Thailand (MOPH).
Matters for Discussion: The meeting will include the initial
review, discussion, and evaluation of applications received in response
to ``Strengthening Disease Prevention Research Capacity for Public
Health Action in Guatemala and the Central American Region'', FOA GH13-
001; ``Addressing Emerging Infectious Diseases in Bangladesh'', FOA
GH14-002; and ``Conducting Public Health Research in Thailand:
Technical collaboration with the Ministry of Public Health in the
Kingdom of Thailand (MOPH)'', FOA GH16-003.
FOR FURTHER INFORMATION CONTACT: Hylan Shoob, Scientific Review
Officer, Center for Global Health (CGH) Science Office, CGH, CDC, 1600
Clifton Road NE., Mailstop D-69, Atlanta, Georgia 30033, Telephone:
(404) 639-4796, HMS4@CDC.GOV.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining to
announcements of meetings and other committee management activities,
for both the Centers for Disease Control and Prevention and the Agency
for Toxic Substances and Disease Registry.
Claudette Grant,
Acting Director, Management Analysis and Services Office, Centers for
Disease Control and Prevention.
[FR Doc. 2017-05733 Filed 3-22-17; 8:45 am]
BILLING CODE 4163-18-P
